US FDA accepts Glenmark’s IND application for GRC 54276 to proceed with Phase 1/2 clinical study for treatment of solid tumors and lymphomas Read more
Blockbuster Enhertu may get tumor agnostic label, targeting any HER2-expressing cancer: GlobalData Read more